Sichenzia Ross Friedman Ference LLP Represents Tonix Pharmaceuticals in $28.7M Public Offering
New York, NY – February 10, 2015 – (Global Newswire) – New York-based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm represented Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, in an underwritten public offering of 4,900,000 shares of common stock at a price of $5.85 per share. The aggregate gross proceeds from the offering were approximately $28.7 million.
Tonix will use the proceeds of the offering to support the continued development of TNX-102 SL for the management of fibromyalgia and post-traumatic stress disorder, to support the development of TNX-201 for the treatment of episodic tension-type headaches, to further develop its other pipeline programs, and for working capital and other general corporate purposes.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner and Associate Sharon Carroll.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)